HST-1021 is a novel mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) allosteric inhibitor identified using the Smart Allostery Platform, and is being developed for the potential treatment of tumors.
Nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) plays a central role in cancer metabolism as well as in metabolism in healthy tissues. Remedy Plan Therapeutics Inc. has presented data on the first hyperbolic Nampt inhibitor – RPT-1G – for the potential treatment of acute myeloid leukemia (AML).
Autologous chimeric antigen receptor (CAR) T-cell therapy has been one of the most recent successes in cancer treatment, but limitations, such as manufacturing, costs or antigen escape in therapies directed against only one target that leads to resistance, highlight the need for new approaches. Classical natural killer T (NKT) cells engineered to express CARs constitute a novel type of allogeneic therapy that does not require T-cell receptor (TCR) gene editing, thus avoiding graft-vs.-host disease (GVHD).
MYB is a transcription factor essential for cell proliferation and differentiation, and is regarded as a target for cancer therapy because it is overexpressed in many different tumor types such as adenoid cystic carcinoma (ACC), acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia, among others.
Researchers have developed a novel chronic lymphocytic leukemia (CLL) murine model that expresses human BCL2 in B cells under the TCL1 promoter control, named TBC.
It is known that CD19-directed CAR T-cell therapy is useful in the treatment of large B-cell lymphoma, but about 60% of patients relapse after treatment, and about 30% of these are CD19-negative patients with poor survival. Sana Biotechnology Inc. is developing a hypoimmune CD22-directed CAR T-cell therapy, named SC-262, for the potential treatment of large B-cell lymphoma.
A sustained antiplatelet effect plus target selectivity are the two major requirements for developing new antithrombotic therapies. Increasing the levels of cAMP in the platelets by the action of a prostacyclin receptor (PTGIR) agonist is a possible approach for this purpose. Researchers from the University of Michigan have presented preclinical data on their PTGIR agonist CS-585, which has shown higher blood stability, as a potential therapeutic for thrombosis.
Previous studies with mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors have demonstrated their potential as antitumor agents across several tumor models when administered alone or in combination with standard treatments.
CD33 is known to be highly expressed in myeloid cells and a good therapeutic target for treating acute myeloid leukemia (AML). In the search for more potent compounds, researchers from Dragonfly Therapeutics Inc. and Bristol Myers Squibb Inc. investigated the therapeutic potential of BMS-986357, also known as CC-96191.
Myeloproliferative neoplasms (MPNs) are a group of disorders of which the main hallmarks are bone marrow fibrosis and atypical megakaryocytes (MK) accumulation. Both Rho kinase (ROCK) and Aurora kinase (ARK) pathways are involved in correct MK maturation.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
